Atossa Genetics Announces $30 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital, LLC

Initial Purchase of 83,333 Shares at $12.00 per Share

Marketwired

SEATTLE, WA--(Marketwire - Mar 28, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), a healthcare company focused on the prevention of breast cancer, has entered into a $30 million stock purchase agreement with Aspire Capital, LLC. Under terms of the agreement, Aspire has made an initial purchase of $1 million of Atossa common stock at a price of $12.00 per share. In addition, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to an additional $29 million of Atossa's common stock over the next three years at prices based on prevailing market prices over a period preceding each sale.

"We look forward to working with Aspire Capital as a financial partner and to Aspire Capital being a long-term investor in Atossa," stated Dr. Steven Quay, chairman, CEO and president. "Our agreement with Aspire provides added financial strength and flexibility, allowing us to raise equity opportunistically based on market conditions and our working capital needs. We believe that Aspire's initial investment and ongoing commitment, along with their reputation as a long-term, institutional investor, demonstrates confidence in our ForeCYTE and ArgusCYTE tests, other breast health tests in development, and our business model. We presently do not expect to need to raise additional equity capital in the near term other than under this agreement. However, we may decide to opportunistically raise equity or debt capital or enter into a strategic transaction in which equity capital is issued."

"Over the past few months we have spent a lot of time with the management team and done significant due diligence on Atossa as well as talked with physicians and users of its products. During this process, we have come to see the tremendous opportunity that Atossa presents as the 'Pap Smear' for the breast and for early non-invasive treatment of breast cancer," commented Steven G. Martin, Managing Member of Aspire Capital. "Atossa's products can help save the lives of our mothers, our daughters and our wives. The Company's success is personal to all of us. We are extremely proud to be a long-term shareholder in Atossa and a financial partner to this experienced management team."

Key aspects of the agreement with Aspire Capital include:

  • $30 million financing with $1 million of common stock sold at $12.00 per share by Atossa on March 27, 2013;
  • Atossa will control the timing and amount of any additional sales of common stock to Aspire and will know the sales price before directing Aspire to purchase shares;
  • Aspire has no right to require any sales by Atossa, but is obligated to make purchases as Atossa directs, in accordance with the terms of the purchase agreement;
  • Aspire has agreed to a long-only position;
  • There are no limitations on use of proceeds, financial covenants, restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement;
  • The purchase agreement may be terminated by Atossa at any time, at its discretion, without any additional cost or penalty; and
  • Atossa has issued shares of its common stock to Aspire Capital as a commitment fee in connection with entering into the purchase agreement.

Atossa will use the net proceeds from the sales of common stock for general corporate purposes and working capital requirements. Dawson James Securities, Inc. was the placement agent for the sale of 83,333 shares of common shares at $12 per share as well as the $30 million stock purchase agreement.

Atossa also entered into a registration rights agreement with Aspire in connection with its entry into the purchase agreement that requires the Company to file a registration statement regarding the shares sold to Aspire Capital. A more complete and detailed description of the transaction is set forth in the Company's Annual Report on Form 10-K, filed today with the U.S. Securities and Exchange Commission.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

About Aspire Capital Fund, LLC

Aspire Capital Fund, LLC is an institutional investor based in Chicago, Illinois, with a fundamental investment approach. Aspire Capital Invests in a wide range of companies and industries emphasizing life sciences, energy and technology.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, ability to sell shares to Aspire, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed January 28, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

View Comments